Torsades de pointes associated with methadone and voriconazole

BMJ Case Reports

Volumn , Issue , 2009, Pages

  Reinhold, Jennifer A ^a   Sanoski, Cynthia A ^b   Russo, Andrea M ^c   Cooper, Joshua M ^d   Spinler, Sarah A ^a,d  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c Department of Anesthesiology   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84897878014     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr.07.2009.2119     Document Type: Article

References (41)

1. Tan HL, Hou CJY, Lauer MR, et al. Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes. Ann Intern Med 1995; 122: 701-14. [CrossRef] [Medline] [Web of Science]
2. Atkinson D, Dunne A, Parker M. Torsades de pointes and self-terminating ventricular fibrillation in a prescription methadone user. Anaesthesia 2007; 62: 952-5. [CrossRef] [Medline] [Web of Science] (Pubitemid 47261803)
3. Kornick CA, Kilborn MJ, Santiago-Palma J, et al. QTc interval prolongation associated with intravenous methadone. Pain 2003; 105: 499-506. [CrossRef] [Medline] [Web of Science] (Pubitemid 37186911)
4. Gupta A, Lawrence A, Krishnan K, et al. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J 2007; 153: 891-9. [CrossRef] [Medline] [Web of Science] (Pubitemid 46809861)
5. Wedam EF, Bigelow GE, Johnson RE, et al. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007; 167: 2469-75. [CrossRef] [Medline] [Web of Science] (Pubitemid 350254906)
6. Iskandar SB, Abi-Saleh BS, Mechleb BK, et al. Methadone and torsade de pointes: case report and review of the literature. Tenn Med 2007; 100: 35-7. [Medline]
7. Ehret GB, Voide C, Gex-Fabry M, et al. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med 2006; 166: 1280-7. [CrossRef] [Medline] [Web of Science] (Pubitemid 43967579)
8. Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf 2005; 14: 747-53. [CrossRef] [Medline] [Web of Science] (Pubitemid 41684467)
9. Peles E, Bodner G, Kreek MJ, et al. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: a cross-sectional study. Addiction 2007; 102: 289-300. [Medline] [Web of Science] (Pubitemid 46096291)
10. Routhier DD, Katz KD, Brooks DE. QTc prolongation and torsades de pointes associated with methadone therapy. J Emerg Med 2007; 33: 275-8. Search Google Scholar (Pubitemid 46467247)
11. Krantz MJ, Lewkowiez L, Hays H, et al. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 2002; 137: 501-4. [CrossRef] [Medline] [Web of Science] (Pubitemid 35024621)
12. Sticherling C, Schaer BA, Ammann P, et al. Methadone-induced torsade de pointes tachy cardias. Swiss Med Wkly 2005; 135: 282-5. [Medline] (Pubitemid 40827287)
13. Gil M, Sala M, Anguera I, et al. QT prolongation and torsades de pointes in patients infected with human immunodeficiency virus and treated with methadone. Am J Cardiol 2003; 92: 995-7. [CrossRef] [Medline] [Web of Science] (Pubitemid 37214820)
14. Ehert G, Desmeules JA, Broers B. Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned from pharmacology. Expert Opin Drug Saf 2007; 6: 289-303. [CrossRef] [Medline] [Web of Science] (Pubitemid 46767636)
15. Lamont P, Hunt SC. A twist on torsade: a prolonged QT interval on methadone. J Gen Intern Med 2006; 21: C9-C12. [CrossRef] [Medline] [Web of Science] (Pubitemid 44506863)
16. Eiden C, Peyriere H, Tichit R, et al. Inherited long QT syndrome revealed by antifungals drug-drug interaction. J Clin Pharm Ther 2007; 31: 321-4. Search Google Scholar (Pubitemid 46699512)
17. Alkan Y, Haefeli WE, Burhenne J, et al. Voriconazole-induced QT interval prolongation and ventricular tachycardia: a non-concentration-dependent adverse effect. Clin Infect Dis 2004; 39: e49-52. [Abstract/FREE Full text]
18. Philips JA, Marty FM, Stone RM, et al. Torsades de pointes associated with voriconazole use. Transpl Infect Dis 2007; 9: 33-6. [CrossRef] [Medline] [Web of Science]
19. Nordin C, Kohli A, Beca S, et al. Importance of hepatitis C coinfection in the development of QT prolongation in HIV-infected patients. J Electrocardiol 2006; 39: 199-205. [CrossRef] [Medline] [Web of Science]
20. Villa A, Cruccu V, Confalonieri F. QT interval prolongation and HIV-related autonomic neuropathy. Int Conf AIDS 1993; 9: 414. Search Google Scholar
21. Hrovatin E, Zardo F, Brieda M, et al. Long QT and torsade de pointes in a patient with acquired human immunodeficiency virus infection in multitherapy with drugs affecting cytochrome P450. Ital Heart J Suppl 2004; 5: 735-40. [Medline]
22. Krantz MJ, Rowan SB, Mehler PS. Cocaine-related torsade de pointes in a methadone maintenance patient. J Addict Dis 2005; 24: 53-60. [CrossRef] [Medline] [Web of Science] (Pubitemid 40209081)
23. Bauman JL, DiDomenico RL. Cocaine-induced channelopathies: emerging evidence on the multiple mechanisms of sudden death. J Cardiovasc Pharmacol Ther 2002; 7: 195-202. [Abstract/FREE Full text] (Pubitemid 36056000)
24. Indiana University School of Medicine. P450 Table, version 5.0 (released 12 January 2009). http://medicine.iupui.edu/flockhart/table.htm (accessed 8 October 2009).
25. Crettol S, Deglon JJ, Besson J, et al. Methadone enantiomer plasma levels CYB2D6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 2005; 78: 593-604. [CrossRef] [Medline] [Web of Science] (Pubitemid 41773635)
26. Liu P, Foster G, LaBadie R, et al. Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy. Antimicrob Chemother 2007; 51: 110-8. [Abstract/FREE Full text] (Pubitemid 46047695)
27. Jeong S, Nguyen PD, Desta Z. Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob Agents Chemother 2009; 53: 541-51. [Abstract/FREE Full text]
28. Li Y, Kantelip JP, Gerritsen-van Schieveen P, et al. Interindividual variability of methadone response: impact of genetic polymorphism. Mol Diagn Ther 2008; 12: 109-24. [Medline] [Web of Science] (Pubitemid 351570866)
29. Totah RA, Sheffels P, Roberts T, et al. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 2008; 108: 363-74. [Medline] [Web of Science] (Pubitemid 351304229)
30. Lipski J, Stimmel B, Donoso E. The effect of heroin and multiple drug use on the electrocardiogram. Am Heart J 1973; 86: 663-8. [CrossRef] [Medline] [Web of Science]
31. Owens RC, Nolin TD. Antimicrobial associated QT interval prolongation: points of interest. Clin Infec Dis 2007; 43: 1603-11. [CrossRef]
32. Tian M, Dong MQ, Chiu SW, et al. Effects of the antifungal antibiotic clotrimazole on human cardiac repolarization potassium currents. Br J Pharmacol 2006; 147: 289-97. [CrossRef] [Medline] [Web of Science] (Pubitemid 43214686)
33. Kikuchi K, Nagatomo T, Abe H, et al. Blockade of HERG cardiac K+ current by antifungal drug miconazole. Br J Pharmacol 2005; 144: 840-8. [CrossRef] [Medline] [Web of Science] (Pubitemid 40516123)
34. Makkar RR, Fromm BS, Steinman RT, et al. Female gender as a risk factor associated with torsade de pointes associated with cardiovascular drugs. JAMA 1993; 270: 2590-7. [CrossRef] [Medline] [Web of Science] (Pubitemid 23346699)
35. James AF, Choisy SC, Hancox JC. Recent advances in understanding sex differences in cardiac repolarization. Prog Biophys Mol Biol 2007; 94: 265-319. [CrossRef] [Medline] [Web of Science] (Pubitemid 46766581)
36. Pfizer. Voriconazole (Vfend®) package insert. New York, USA: Pfizer, 2006. Search Google Scholar
37. Niwa T, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 2005; 28: 1805-8. [CrossRef] [Medline] [Web of Science] (Pubitemid 41324160)
38. Ingelheim Boeringher. Nev irapine (Viramune®) package insert. Columbus, Ohio, USA: Boeringher Ingelheim, 2007. Search Google Scholar
39. Patel AM, Singh JP, Ruskin JM. Role of implantable cardioverter defibrillators in patients with methadone-induced long QT syndrome. Am J Cardiol 2008; 101: 209-11. [CrossRef] [Medline] [Web of Science]
40. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45. [CrossRef] [Medline] [Web of Science] (Pubitemid 12149145)
41. Krantz MJ, Marint J, Stimmel B, et al. QTc interval screening in methadone treatment. Ann Intern Med 2009; 150: 387-95. [CrossRef] [Medline] [Web of Science]